An observational study of dose-optimization for fruquintinib in elderly patients (pts) with metastatic colorectal cancer (mCRC) who had failed standard therapy
机构：[1]Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[2]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[3]Sichuan Cancer Hospital, Sichuan Association of Geriatric Oncology, Chengdu, China四川省肿瘤医院[4]Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
第一作者机构：[1]Department of Abdominal Cancer, Cancer Center, West China Hospital, Sichuan University, Chengdu, China[2]Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China[3]Sichuan Cancer Hospital, Sichuan Association of Geriatric Oncology, Chengdu, China[4]Cancer Center, West China Hospital, Sichuan University, Chengdu, China
推荐引用方式(GB/T 7714)：
Gou Hongfeng,Yu Jing,Cai Xiaohong,et al.An observational study of dose-optimization for fruquintinib in elderly patients (pts) with metastatic colorectal cancer (mCRC) who had failed standard therapy[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):E15560-E15560.
APA：
Gou, Hongfeng,Yu, Jing,Cai, Xiaohong&Li, Qiu.(2022).An observational study of dose-optimization for fruquintinib in elderly patients (pts) with metastatic colorectal cancer (mCRC) who had failed standard therapy.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Gou, Hongfeng,et al."An observational study of dose-optimization for fruquintinib in elderly patients (pts) with metastatic colorectal cancer (mCRC) who had failed standard therapy".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022):E15560-E15560
医学